<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850745</url>
  </required_header>
  <id_info>
    <org_study_id>HMAR-MSP-CHC</org_study_id>
    <nct_id>NCT01850745</nct_id>
  </id_info>
  <brief_title>Multidisciplinary Support Program in Chronic Hepatitis C</brief_title>
  <official_title>Evaluation of a multid√¨sciplinary Support Program in the Adherence and Efficacy of Peginterferon Alfa-2a and Ribavirin Therapy in Chronic Hepatitis C.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to
      achieve sustained virological response (SVR). The aim of our study is to evaluate the
      efficacy of a multidisciplinary support program (MSP) in adherence to and efficacy of
      pegylated interferon alfa-2a and ribavirin compared to the conventional approach. We assessed
      447 patients with CHC receiving antiviral treatment distributed into 3 groups: control group
      (recruited 2002-2004, n= 147), MSP-pilot group (recruited 2005-2006, n=131), and
      MSP-validation group (recruited 2007-2009, n=169).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to
      achieve sustained virological response (SVR). The aim of our study is to evaluate the
      efficacy of a multidisciplinary support program (MSP) in adherence to and efficacy of
      pegylated interferon alfa-2a and ribavirin compared to the conventional approach. We assessed
      447 patients with CHC receiving antiviral treatment distributed into 3 groups: control group
      (follow-up 2002-2004, n= 147), MSP-pilot group (follow-up 2005-2006, n=131), and
      MSP-validation group (follow-up 2007-2009, n=169).A cost-effectiveness analysis was performed
      using a Markov model.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to Treatment</measure>
    <time_frame>48 months</time_frame>
    <description>Adherent patients were defined as those receiving equal or more than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during equal o more than 80% of duration treatment (48 weeks).
Non-adherent patients were defined as those receiving less than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during less than 80% of duration treatment (48 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Treatment Measured by Sustained Virological Response</measure>
    <time_frame>baseline and 72 weeks</time_frame>
    <description>The secondary efficacy end point was to evaluate the sustained virological response (SVR) of antiviral treatment.
SVR was defined as undetectable hepatitis C virus viral load (&lt;15 IU/ml) 24 weeks after treatment completion.
Non-SVR was defined as detectable hepatitis C virus viral load (&gt;15 IU/ml) 24 weeks after treatment completion.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">447</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot cohort</arm_group_label>
    <description>Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multidisciplinary support program</intervention_name>
    <description>Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
    <arm_group_label>Pilot cohort</arm_group_label>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C virus infection (CHC)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic hepatitis C eligible to receive antiviral treatment.

        Exclusion Criteria:

          -  Patients who had undergone previous antiviral treatment, those with human
             immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection, and individuals
             included in other treatment protocols.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricard Sola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hsopital del Mar, Parc de Salut MAR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>September 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2018</results_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Parc de Salut Mar</investigator_affiliation>
    <investigator_full_name>Ricard Sola</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatitis C virus infection (CHC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program</description>
        </group>
        <group group_id="P2">
          <title>Validation Cohort</title>
          <description>Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
        </group>
        <group group_id="P3">
          <title>Pilot Cohort</title>
          <description>Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="131"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program</description>
        </group>
        <group group_id="B2">
          <title>Validation Cohort</title>
          <description>Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
        </group>
        <group group_id="B3">
          <title>Pilot Cohort</title>
          <description>Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="131"/>
            <count group_id="B4" value="447"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="1"/>
                    <measurement group_id="B2" value="42" spread="1"/>
                    <measurement group_id="B3" value="42" spread="1"/>
                    <measurement group_id="B4" value="42" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adherence to Treatment</title>
        <description>Adherent patients were defined as those receiving equal or more than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during equal o more than 80% of duration treatment (48 weeks).
Non-adherent patients were defined as those receiving less than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during less than 80% of duration treatment (48 weeks).</description>
        <time_frame>48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program</description>
          </group>
          <group group_id="O2">
            <title>Validation Cohort</title>
            <description>Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
          </group>
          <group group_id="O3">
            <title>Pilot Cohort</title>
            <description>Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Treatment</title>
          <description>Adherent patients were defined as those receiving equal or more than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during equal o more than 80% of duration treatment (48 weeks).
Non-adherent patients were defined as those receiving less than 80% of total dose of pegylated interferon (180 microg/week) and ribavirin (1200 mg/d) during less than 80% of duration treatment (48 weeks).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="155"/>
                    <measurement group_id="O3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy of Treatment Measured by Sustained Virological Response</title>
        <description>The secondary efficacy end point was to evaluate the sustained virological response (SVR) of antiviral treatment.
SVR was defined as undetectable hepatitis C virus viral load (&lt;15 IU/ml) 24 weeks after treatment completion.
Non-SVR was defined as detectable hepatitis C virus viral load (&gt;15 IU/ml) 24 weeks after treatment completion.</description>
        <time_frame>baseline and 72 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program</description>
        </group>
        <group group_id="E2">
          <title>Validation Cohort</title>
          <description>Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
        </group>
        <group group_id="E3">
          <title>Pilot Cohort</title>
          <description>Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
Multidisciplinary support program: Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="131"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression major</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="147"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="131"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Ricard Sola</name_or_title>
      <organization>Liver Section. Hospital del Mar</organization>
      <phone>0034932483200</phone>
      <email>35783@parcdesalutmar.cat</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

